Gapping down
In reaction to earnings/guidance:
In reaction to earnings/guidance:
- PHAT -10.7% (guidance; also mixed shelf offering; also stock offering by selling shareholders), FC -10.2%, RPM -5.8%, TFX -5.2% (guidance), AYI -4.8%, HELE -4.2%, JEF -3.7%, PSMT -3.2%, LNN -1.8%, ABBV -1.2% (guidance), CRNT -0.9% (guidance), INMD -0.7% (guidance)
Other news:
- IMRX -23.9% (updated overall survival and safety data from its ongoing Phase 2a trial of atebimetinib)
- VNDA -11.5% (announces receipt of FDA decision letter on HETLIOZ supplemental new drug application for jet lag disorder)
- RVMD -7% (lower after AbbVie (ABBV) says it's not in talks to purchase RVMD, according to Bloomberg)
- CSIQ -5.9% (convertible notes offering)
- RPM -5.8% (to acquire Kalzip GmbH)
- RCUS -5.2% (2026 plans for Casdatifan)
- SHEL -2.3% (provides mixed fourth-quarter 2025 outlook with pressure in Chemicals and seasonally weaker Marketing)
- ENTA -1.7% (announces updates on its research and development programs and highlighted upcoming key milestones for 2026)
- DRUG -1% (prices offering of 1.945 mln shares of common stock at $90.00 per share)